Guidance for Industry: Consideration of the Human Health Impact of the Microbial Effects of Antimicrobial New Animal Drugs Intended for Use in Food-Producing Animals (GFI #78); Availability

[Federal Register Volume 64, Number 242 (Friday, December 17, 1999)]
[Notices]
[Pages 70715-70716]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 99-32313]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
[Docket No. 98D-0969]


Guidance for Industry: Consideration of the Human Health Impact 
of the Microbial Effects of Antimicrobial New Animal Drugs Intended for 
Use in Food-Producing Animals (GFI #78); Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is announcing the 
availability of a final guidance document entitled ``Guidance for 
Industry: Consideration of the Human Health Impact of the Microbial 
Effects of Antimicrobial New Animal Drugs Intended for Use in Food-
Producing Animals'' (GFI #78). After the agency considered public 
comments on a draft of this guidance, announced in the Federal Register 
of November 18, 1998, it determined that revision of the draft guidance 
was necessary. GFI #78 announces that FDA believes that it should 
consider the potential human health impact of the microbial effects 
associated with all uses of all classes of antimicrobial new animal 
drugs intended for use in food-producing animals when approving such 
drugs. For additional information regarding the subject matter dealt 
with in GFI #78, see the notice of availability of the document 
entitled ``FDA Response to Comments on a Proposed Framework for 
Evaluating and Assuring the Human Food Safety of the Microbial Effects 
of Antimicrobial New Animal Drugs Intended for Use in Food-Producing

[[Page 70716]]

Animals'' that appears elsewhere in this issue of the Federal Register.

DATES: Submit comments at any time.

ADDRESSES: Submit written comments on GFI #78 to the Dockets Management 
Branch (HFA-305), Food and Drug Administration, rm. 1061, 5630 Fishers 
Lane, Rockville, MD 20852.
     FDA will also accept electronic comments. Persons who wish to 
submit electronic comments should go to the FDA home page at 
www.fda.gov and select ``Dockets'' and follow the instructions.
    Submit written requests for single copies of the document entitled 
``Guidance for Industry: Consideration of the Human Health Impact of 
the Microbial Effects of Antimicrobial New Animal Drugs Intended for 
Use in Food-Producing Animals'' (GFI #78) to the Communications Staff 
(HFV-12), Center for Veterinary Medicine, Food and Drug Administration, 
7500 Standish Pl., Rockville, MD 20855. Send one self-addressed 
adhesive label to assist that office in processing your requests. See 
section III. Electronic Access of this document for information on 
electronic access to the guidance document.

FOR FURTHER INFORMATION CONTACT: Sharon Thompson, Center for Veterinary 
Medicine (HFV-1), Food and Drug Administration, 7500 Standish Pl., 
Rockville, MD 20855, 301-594-1798, e-mail: sthompso@cvm.fda.gov.

SUPPLEMENTARY INFORMATION: 

I. Background

    In the Federal Register of November 18, 1998 (63 FR 64094), FDA 
announced the availability of a draft guidance entitled ``Guidance for 
Industry: Evaluation of the Human Health Impact of the Microbial 
Effects of Antimicrobial New Animal Drugs Intended for Use in Food-
Producing Animals'' (GFI #78). This draft guidance announced that FDA 
believed that it should evaluate the human health impact of the 
microbial effects associated with all uses of all classes of 
antimicrobial new animal drugs intended for use in food-producing 
animals when approving such drugs. The publication of the draft of GFI 
#78 was the first step in the agency's consideration of the issues 
related to the use of antimicrobial new animal drugs in food-producing 
animals. The draft of GFI #78 laid out the agency's rationale for its 
current thinking about its authority under the Federal Food, Drug, and 
Cosmetic Act to consider the human health impact of the microbial 
effects associated with the use of antimicrobial new animal drugs in 
food-producing animals.
    In the Federal Register of January 6, 1999 (64 FR 887), FDA 
announced the availability of a discussion paper entitled ``A Proposed 
Framework for Evaluating and Assuring the Human Safety of the Microbial 
Effects of Antimicrobial New Animal Drugs Intended for Use in Food-
Producing Animals'' (Framework Document). The Framework Document was 
the second step in the agency's consideration of issues related to the 
use of antimicrobial new animal drugs in food-producing animals. FDA 
made the Framework Document available to the public to initiate 
discussions with the scientific community and other interested parties 
on the agency's thinking about appropriate underlying concepts to be 
used to develop microbial safety policies protective of the public 
health. The Framework Document is related to GFI #78 in that it sets 
out a conceptual risk-based framework for evaluating the microbial 
safety (related to human health impact) of antimicrobial new animal 
drugs intended for use in food-producing animals.
    After considering comments received by the public for both the 
draft of GFI #78 and the Framework Document, FDA determined that it was 
necessary to make some revisions to GFI #78. The revisions are intended 
to make GFI #78 more clearly reflect the agency's intentions regarding 
this issue. For example, the words ``evaluate'' and ``evaluation'' have 
been changed to ``consider'' and ``consideration,'' and other changes 
have been made to indicate that additional testing would not always be 
needed to determine the potential human health impact of the microbial 
effects associated with antimicrobial new animal drugs intended for use 
in food-producing animals.
    GFI #78 represents the agency's current thinking that it should 
consider the potential human health impact of the microbial effects 
associated with all uses of all classes of antimicrobial new animal 
drugs intended for use in food-producing animals when approving such 
drugs. It does not create or confer any right for or on any person and 
does not operate to bind FDA or the public. An alternative approach may 
be used if such approach satisfies the requirements of the applicable 
statute, regulations, or both.

II. Comments

    Interested persons may, at any time, submit written or electronic 
comments on GFI #78 to the Dockets Management Branch (address above). 
Two copies of written comments are to be submitted, except that 
individuals may submit one copy. All comments are to be identified with 
the docket number found in brackets in the heading of this document. 
GFI #78 and written and electronic comments are available for public 
examination in the Dockets Management Branch between 9 a.m. and 4 p.m., 
Monday through Friday.

III. Electronic Access

    Persons with access to the Internet may obtain copies of ``Guidance 
for Industry: Consideration of the Human Health Impact of the Microbial 
Effects of Antimicrobial New Animal Drugs Intended for Use in Food-
Producing Animals'' (GFI #78) at http://www.fda.gov/cvm.

    Dated: December 8, 1999.
Margaret M. Dotzel,
Acting Associate Commissioner for Policy.
[FR Doc. 99-32313 Filed 12-14-99; 4:09 pm]
BILLING CODE 4160-01-F